Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Revenue (2016 - 2025)

Mimedx's Revenue history spans 15 years, with the latest figure at $118.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 27.11% year-over-year to $118.1 million; the TTM value through Dec 2025 reached $418.6 million, up 19.99%, while the annual FY2025 figure was $418.6 million, 19.99% up from the prior year.
  • Revenue for Q4 2025 was $118.1 million at Mimedx, up from $113.7 million in the prior quarter.
  • Across five years, Revenue topped out at $118.1 million in Q4 2025 and bottomed at $50.8 million in Q4 2021.
  • The 5-year median for Revenue is $81.5 million (2023), against an average of $79.9 million.
  • The largest annual shift saw Revenue fell 25.87% in 2021 before it skyrocketed 46.37% in 2022.
  • A 5-year view of Revenue shows it stood at $50.8 million in 2021, then skyrocketed by 46.37% to $74.4 million in 2022, then grew by 16.75% to $86.8 million in 2023, then increased by 7.0% to $92.9 million in 2024, then rose by 27.11% to $118.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Revenue are $118.1 million (Q4 2025), $113.7 million (Q3 2025), and $98.6 million (Q2 2025).